Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease

被引：6

作者：

Al Sulais, Eman ^{[1
]}

AlAmeel, Turki ^{[2
]}

机构：

[1] Royal Commiss Hosp, Dept Med, POB 496, Jubail Ind City 31911, Qatif, Saudi Arabia

[2] King Fahad Specialist Hosp, Dept Med, Dammam, Saudi Arabia

来源：

BIOLOGICS-TARGETS & THERAPY | 2020年 / 14卷

关键词：

biosimilars; inflammatory bowel disease; tumor necrosis factor inhibitors; ACTIVE RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; DOUBLE-BLIND; INNOVATOR INFLIXIMAB; POSITION STATEMENT; ULCERATIVE-COLITIS; PARALLEL-GROUP; ANTIBODIES; EFFICACY; SAFETY;

D O I：

10.2147/BTT.S236433

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Health care providers ought to be aware of the available data that addresses the safety and efficacy of biosimilars in IBD patients. This article outlines the current evidence-based data regarding the available biosimilar products, their safety, efficacy and how to deal with patients' concerns.

引用

页码：1 / 11

页数：11

共 50 条

[41] Antitumor Necrosis Factor-α Therapy Associated with Inflammatory Bowel Disease: Three Cases and a Systematic Literature Review
Bieber, Amir
Fawaz, Abdallah
Novofastovski, Irina
Mader, Reuven
JOURNAL OF RHEUMATOLOGY, 2017, 44 (07) : 1088 - 1095
[42] Therapeutic drug monitoring of anti-tumour necrosis factor-a agents in inflammatory bowel disease
Mitrev, Nikola
Leong, Rupert W.
EXPERT OPINION ON DRUG SAFETY, 2017, 16 (03) : 303 - 317
[43] Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease
Cohen, Benjamin L.
Sachar, David B.
BMJ-BRITISH MEDICAL JOURNAL, 2017, 357
[44] Placental Transfer of Anti-Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease
Mahadevan, Uma
Wolf, Douglas C.
Dubinsky, Marla
Cortot, Antoine
Lee, Scott D.
Siegel, Corey A.
Ullman, Thomas
Glover, Sarah
Valentine, John F.
Rubin, David T.
Miller, Jocelyn
Abreu, Maria T.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (03) : 286 - 292
[45] The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease
Koutroubakis, Ioannis E.
Ramos-Rivers, Claudia
Regueiro, Miguel
Koutroumpakis, Efstratios
Click, Benjamin
Schwartz, Marc
Swoger, Jason
Baidoo, Leonard
Hashash, Jana G.
Barrie, Arthur
Dunn, Michael A.
Binion, David G.
INFLAMMATORY BOWEL DISEASES, 2015, 21 (07) : 1587 - 1593
[46] Study of tumor necrosis factor receptor in the inflammatory bowel disease
Roberta Figueiroa Souza
Marcos Ant?nio Ferreira Caetano
Henrique Inhauser Riceti Magalh?es
Patricia Castelucci
World Journal of Gastroenterology, 2023, (18) : 2733 - 2746
[47] Study of tumor necrosis factor receptor in the inflammatory bowel disease
Souza, Roberta Figueiroa
Caetano, Marcos Antonio Ferreira
Magalhaes, Henrique Inhauser Riceti
Castelucci, Patricia
WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (18) : 2733 - 2746
[48] Tumor necrosis factor family members and inflammatory bowel disease
Wang, J
Fu, YX
IMMUNOLOGICAL REVIEWS, 2005, 204 : 144 - 155
[49] Exit strategies in inflammatory bowel disease: Looking beyond antitumor necrosis factors
Crispino, Federica
Michielan, Andrea
Grova, Mauro
Tieppo, Chiara
Mazza, Marta
Rogger, Teresa Marzia
Armelao, Franco
WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (12)
[50] Antitumor Necrosis Factor, Infliximab, and Adalimumab: Use With Caution in Eosinophilic Bowel Disease
Furuta, Glenn T.
Atkins, Dan
Capocelli, Kelley E.
de Zoeten, Edwin F.
Fleischer, David
Menard-Katcher, Calies
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2013, 57 (04):

← 1 2 3 4 5 →